PROJECTS IN LINE

FOCUSING ON PN6047

A woman sitting down in a test lab looking at some test tubes

Therapeutic focus » Projects

A compound with therapeutic potential

PharmNovo aims to develop novel drugs with superior clinical properties to treat patients with neuropathic pain.

Our lead compound PN6047 is a novel potent, selective and biased signalling delta opioid receptor agonist, which is predicted to reduce common symptoms of neuropathic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.

PharmNovo’s drug candidate PN6047 also addresses another problem: neuropathic pain patients frequently suffer from associated anxiety and depression, which exacerbates their pain and generates a vicious cycle of low mood and increasing pain.  DOR agonists can attenuate both pain and the associated emotional disorders.

In various pre-clinical studies, PN6047 has shown high selectivity and potency and very convincing efficacy in reducing neuropathic pain without any signs of the unwanted side effects of traditional opioids, such as respiratory depression, abuse potential and the development of tolerance.

PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favourable dosing in humans.

PN6047 has fully drug-able properties and characteristics enabling the production of a commercial solid dosage form.

PharmNovos' current focus is on demonstrating efficacy through Phase IIA Proof of Concept studies in one or more patient populations starting in 2024.

Prior to 2020

Establishing the baseline

  • PN6047 developed
  • Convincing pre-clinical efficacy data
  • Patent applications in significant markets
2020-2023

Setting the scene

  • GMP compound production and process development
  • Toxicology studies to support clinical studies
  • Phase I and clinical target engagement studies
  • Secure patent protection in all major markets
2023-

Milestones

  • Establishing efficacy and defining  market
  • Phase IIA PoC efficacy studies in one or more patient populations
  • Identification of VC/Pharma partner
  • Alignment of path to market with regulatory authorities, in particular, EMA and FDA

Latest news

View all
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more